Reading the tape
NYSE: PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General
Market Cap
$149.77B
52w High
$28.75
52w Low
$21.97
P/E
19.26
Volume
29.54M
Outstanding Shares
5.69B
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 10.31%Revenue (TTM): -1.65%FCF (TTM): -7.72%P/FCF: 67th pct
What changed
The stock rose 10.31% over the last year. Revenue declined 1.65% over the trailing twelve months. Operating margin moved from 26.92% to 24.67%. Free cash flow declined 7.72% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 24.67%. A decisive move in revenue — currently down 1.65% — would be the clearest signal to resolve the ambiguity.
Company profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
CEOAlbert Bourla
SectorHealthcare
IndustryDrug Manufacturers - General
Employees81,000
IPO dateJun 1, 1972
Valuation
Forward P/E—
EV/EBITDA13.76
Enterprise value$207.77B
Stock splits
Nov 17, 2020↑ Forward
Every 500 shares became 527
Jul 1, 1999↑ Forward
Every 1 shares became 3
Jul 1, 1997↑ Forward
Every 1 shares became 2
Jul 3, 1995↑ Forward
Every 1 shares became 2
Apr 1, 1991↑ Forward
Every 1 shares became 2
Jul 1, 1983↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth-1.16%
Gross margin70.33%▲6.94%vs FY2024
Operating margin24.67%▼4.78%vs FY2024
ROE8.99%▼1.18%vs FY2024
Analyst consensus
RatingHold
Target price$27.27▲3.57%
16
Buy
21
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $0.71 · Revenue est $13.84B
View
Dividends
$1.72/shareQuarterlyDividend Achiever · 16yrEx-div May 8, 2026 · in 3dStretchedPFE pays a dividend with a 6.53% declared yield, 16 consecutive years of growth, growing at 2.24% annually, covered 0.9× by free cash flow.
Declared Yield
6.53%
Annual Div / Share
$1.72
5yr CAGR
+2.24%
Doubles every ~31.4yr
Payout Ratio
125.75%
Stretched
Dividend Growth Rate
3yr CAGR
+2.02%
5yr CAGR
+2.24%
10yr CAGR
+4.31%
Dividend Safety
2/10Stretched
Dividend History
Annualized dividend cycles per share
YearAnnual DivYoY
2026$1.72+1.2%
2025$1.70+2.4%
2024$1.66+2.5%
2023$1.62+2.5%
2022$1.58+2.6%
2021$1.54+4.1%
2020$1.48+5.7%
Income Projection
Invest
$
Growth rate:
Reinvest dividends
Today
$65/yr
$5/mo
In 5 yrs
$73/yr+12%
$6/mo
In 10 yrs
$81/yr+25%
$7/mo
| Today | In 5 yrs | In 10 yrs |
|---|---|---|
$65/yr $5/mo | $73/yr+12% $6/mo | $81/yr+25% $7/mo |
Yield-on-cost grows from 6.53% → 8.15% over 10yr
Analysis
Dividend Strengths
Dividend Achiever
PFE has raised its dividend for 16 consecutive years — qualifying as a Dividend Achiever, demonstrating long-term commitment to shareholder income.
Risks to Watch
High payout ratio
With 125.75% of earnings paid as dividends, there is limited retained earnings for reinvestment — and a dividend cut becomes more likely if earnings decline.
Dividend exceeds free cash flow
Free cash flow covers only 0.93× the dividend. The company is paying out more than it generates in cash, which is unsustainable without borrowing or asset sales.
Congressional Activity
Congress Trades in PFE
STOCK Act disclosures from senators and representatives.
- SC
Susan M. Collins
MEsenateRepublicanPurchaseSpouse2026-02-03$15,001 - $50,000+50d to disclose